TRICARE, the healthcare program for active and retired US military personnel and their families, has added a new insomnia therapy, Idorsia Pharmaceuticals US Inc’s QUVIVIQ (daridorexant) CIV, to its Uniform Formulary.
QUVIVIQ was approved in January 2022 for the treatment of adults who have trouble falling asleep or staying asleep. It is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain.
“This is a big win for patients suffering from insomnia,” says Patty Torr, Idorsia US president and general manager, in a release. “Sadly, the rate of sleep issues experienced by our service members and their families is far higher than what we find in general society. With TRICARE adding QUVIVIQ to their formulary we hope many of our country’s service members and their loved ones with insomnia will finally be able to get the sleep they need and deserve.”
